Salmonella enterica serovar Typhi (S. Typhi) differs from most other salmonellae in that it causes a life-threatening systemic infection known as typhoid fever 1 . The molecular bases for its unique clinical presentation are unknown 2 . Here we find that the systemic administration of typhoid toxin, a unique virulence factor of S. Typhi, reproduces many of the acute symptoms of typhoid fever in an animal model. We identify specific carbohydrate moieties on specific surface glycoproteins that serve as receptors for typhoid toxin, which explains its broad cell target specificity. We present the atomic structure of typhoid toxin, which shows an unprecedented A 2 B 5 organization with two covalently linked A subunits non-covalently associated to a pentameric B subunit. The structure provides insight into the toxin's receptor-binding specificity and delivery mechanisms and reveals how the activities of two powerful toxins have been co-opted into a single, unique toxin that can induce many of the symptoms characteristic of typhoid fever. These findings may lead to the development of potentially lifesaving therapeutics against typhoid fever.
Salmonella enterica serovar Typhi (S. Typhi) differs from most other salmonellae in that it causes a life-threatening systemic infection known as typhoid fever 1 . The molecular bases for its unique clinical presentation are unknown 2 . Here we find that the systemic administration of typhoid toxin, a unique virulence factor of S. Typhi, reproduces many of the acute symptoms of typhoid fever in an animal model. We identify specific carbohydrate moieties on specific surface glycoproteins that serve as receptors for typhoid toxin, which explains its broad cell target specificity. We present the atomic structure of typhoid toxin, which shows an unprecedented A 2 B 5 organization with two covalently linked A subunits non-covalently associated to a pentameric B subunit. The structure provides insight into the toxin's receptor-binding specificity and delivery mechanisms and reveals how the activities of two powerful toxins have been co-opted into a single, unique toxin that can induce many of the symptoms characteristic of typhoid fever. These findings may lead to the development of potentially lifesaving therapeutics against typhoid fever.
Salmonella enterica serovar Typhi (S. Typhi), the cause of typhoid fever, results in more than 200,000 annual deaths 1, 3, 4 . Unlike other Salmonella serovars, which typically cause self-limiting gastroenteritis, S. Typhi causes a systemic, life-threatening disease 1 . The genome of S. Typhi contains very few unique virulence factors that are not found in non-typhoidal serovars, and the molecular bases for its unique virulence properties and clinical presentation are unknown 5 . One of the few S. Typhi-specific factors that have been shown to directly affect its interaction with host cells is an AB-type toxin dubbed typhoid toxin [6] [7] [8] . Unlike typical AB toxins 9 , typhoid toxin is composed of two A subunits, PltA and CdtB, which are homologues of the A subunits of the pertussis and cytolethal distending toxins, respectively 7 . Its single B subunit, PltB, is a homologue of one of the components of the heteropentameric B subunit of pertussis toxin. Although the cellular targets of the ADP-ribosyl transferase activity of PltA have not yet been identified, CdtB is a DNase that inflicts DNA damage and induces cell-cycle arrest 6, 10, 11 . S. Typhi produces typhoid toxin only within mammalian cells, and the toxin is then ferried to the extracellular environment by a unique transport mechanism that involves vesicle carrier intermediates 7, 8 . Convalescent typhoid fever patients developed strong immune response to the toxin components, indicating that typhoid toxin is produced during human infection 12, 13 . However, the potential contribution of typhoid toxin to disease and pathogenesis is unknown.
We found that systemic administration into mice of a highly purified preparation of biologically active typhoid toxin (Fig. 1a -c) caused many of the symptoms observed during the acute phase of typhoid fever 1, 14 . Despite the lack of fever ( Supplementary Fig. 1 ), the mice appeared lethargic, showing clear signs of stupor and malaise (Supplementary Video 1), lost weight (Fig. 1d ), and eventually died (Fig. 1e) . The toxin-injected animals also showed a significant reduction in the number of circulating immune cells, resulting in the almost complete depletion of circulating neutrophils (Fig. 1f, g) , a phenotype often observed during the acute phase of typhoid fever 14 . Consistent with this observation, typhoid toxin was able to intoxicate a broad range of cells in vitro, including several epithelial and immune cells ( Supplementary  Fig. 2 ). Although symptoms were observed in animals inoculated with a toxin carrying a catalytic mutant of PltA ( Fig. 1d ), no detectable symptoms were observed when animals were inoculated with a toxin carrying a catalytic mutant of CdtB ( Fig. 1d-g) . Taken together, these results indicate that typhoid toxin, through its CdtB subunit, may contribute to the acute symptomatology observed during typhoid fever.
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Monocytes Lymphocytes Neutrophils * 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 CdtB CdtB H160Q H160Q CdtB H160Q Figure 1 | Systemic administration of typhoid toxin causes symptoms observed during the acute phase of typhoid fever. a, Chromatographic profile of the typhoid toxin holotoxin used in the biological assays. The inset shows a Coomassie-blue-stained SDS-PAGE analysis of the peak fraction. AU, absorbance units. b, c, Typhoid toxin induces cell-cycle arrest in cultured cells. Human intestinal epithelial Henle-407 cells were left untreated, or treated with purified typhoid toxin and then analysed by flow cytometry. The insets show representative light microscope images of mock-or toxin-treated cells and is representative of at least three independent experiments. c, Averages of cell cycle profiles from at least three independent experiments. Bar represents average 6 standard deviation. ***P , 0.001, compared to the number of cells in G2M of the control untreated group. UT, untreated; TT, toxin-treated. d, Weight loss 5 days after intravenous administration of different typhoid toxin preparations. Lines are the mean 6 standard error of the mean and represent the weight relative to the values before treatment. ***P , 0.0001. e, Survival of animals receiving different typhoid toxin preparations. n 5 3-5 animals per group. f, Circulating white blood cells were counted in a haematology analyser after the indicated treatments (*P , 0.05). g, Alternatively, the number of neutrophils (vertical dashed line) in peripheral blood of animals treated as indicated was determined by flow cytometry. RFI, relative fluorescence intensity.
To identify the cellular receptor(s) of typhoid toxin, we used a highly purified biologically active typhoid toxin preparation to affinity-purify biotin-labelled host cell-surface-interacting proteins. We found by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses of interacting proteins that, in human epithelial cells, typhoid toxin interacts with podocalyxin-like protein 1 (PODXL) ( Fig. 2a, b ), a member of the CD34 sialomucin protein family, which localizes to the apical side of epithelial cells and is also expressed in vascular endothelial cells 15 . Consistent with its potential role as a toxin receptor, short hairpin RNA (shRNA)-mediated depletion of PODXL resulted in a significant reduction in toxin binding ( Fig. 2c and Supplementary Fig. 3 ) and toxinmediated cell-cycle arrest (Fig. 2d ). Because we found that typhoid toxin is capable of intoxicating a broad range of cells ( Supplementary Fig. 2 ), we examined the interaction of typhoid toxin with surface proteins of other cell lines. We found that in macrophages as well as in T and B cells, typhoid toxin interacts with receptor tyrosine phosphatase C, also known as CD45 ( Supplementary Fig. 4 ), which is ubiquitously expressed in haematopoietic cells other than erythrocytes and platelets 16 . These results indicate that typhoid toxin may engage different receptors in different cells. The identified typhoid toxin-interacting proteins, however, are all glycosylated, indicating that typhoid toxin may interact with these different surface proteins through common carbohydrate moieties. Consistent with this hypothesis we found that removal of surface glycans significantly reduced typhoid toxin binding to cultured cells ( Fig. 2e ). Furthermore, a cell line lacking all complex and hybrid N-glycans on glycoproteins due to a mutation in N-acetylglucosaminyltransferase I 17, 18 was more resistant to typhoid toxin than its parent wild-type cell line ( Fig. 2f , g and Supplementary Fig. 5 ). These results indicate that a sugar moiety(s) on surface glycoproteins serves as a receptor for typhoid toxin.
To identify the glycans recognized by typhoid toxin we probed 610 glycans arrayed on a solid surface 19 for binding to biologically active, highly purified, fluorescently labelled typhoid toxin. This analysis revealed a complex binding pattern involving four main glycan groups ( Fig. 2h and Supplementary Tables 1 and 2 ). The first group, which is most commonly present in complex N-linked glycans, is represented by sialylated tri-or biantennary glycans (for example, glycans nos 461, 483 and 482) with one or all of the branches terminally sialyated (note: glycan numbers correspond to the nomenclature used by the Consortium for Functional Glycomics, http://www.functionalglycomics.org). This group includes glycans with both a(2-3)-linked N-acetylneuraminic acid (Neu5Aca2-3; for example, no. 483) and a(2-6)-linked N-acetylneuraminic acid (Neu5Aca2-6; for example, no. 482) terminal linkages. However, typhoid toxin probably binds preferentially to Neu5Aca2-3 terminal linkages because glycan 483 showed stronger binding than glycan 482, which only differ in their terminal linkages ( Fig. 2h and Supplementary Tables 1 and 2 ). Furthermore, typhoid toxin is likely to bind tri-antennary compounds preferentially over bi-antennary compounds, because glycan 461 showed the highest binding affinity. In addition, the toxin may also bind preferentially the type 2-N-acetyllactosamine unit (Galb1-4GlcNAc), present in glycan 461, over type 1-N-acetyllactosamine unit (Galb1-3GlcNAc), present in the very similar tri-antennary N-glycan 474, which showed lower binding affinity ( Fig. 2h and Supplementary Tables 1 and 2 ). The second group consists of non-sialylated tri-or bi-antennary glycans also commonly found in complex N-linked glycans. Overall this group had lower binding affinity than sialylated glycans, implying a preference of typhoid toxin for the terminal sialic acid modification. The third group consists of glycans commonly found in glycolipids, mostly as gangliosides. Among these glycans typhoid toxin likely prefers Neu5Aca2-8Neu5Ac disialosides, present in ganglioside GD2 20 (glycan 228), over Neu5Ac monosialoside, present in GM3 (glycan 263), which did not bind the toxin. These results indicate that, in certain cells, typhoid toxin may also be able to use glycolipids as a receptor. Consistent with this hypothesis, typhoid toxin was able to intoxicate an N-acetylglucosaminyltransferase I-deficient cell line, although only when applied at high concentrations ( Supplementary  Fig. 6 ). The fourth group is defined by glycans commonly found on O-glycans, such as glycan 243, which shares the canonical structure of mucin type O-Gal N-acylated glycan. Taken together, these results indicate that typhoid toxin can use as receptors a broad range of glycans, preferentially on surface glycoproteins, but also, although less efficiently, on surface glycolipids, providing a mechanistic explanation for its broad cell target specificity.
To uncover the organization of typhoid toxin, we solved its crystal structure to 2.4 Å resolution. The structure showed a complex of five PltB molecules and one molecule each of PltA and CdtB ( Fig. 3a and Supplementary Table 3 ), which is consistent with the stoichiometry observed by size-exclusion chromatography combined with dynamic light scattering and quantitative amino acid composition analysis ( Supplementary Fig. 7 ). This indicates an unprecedented A 2 B 5 organization for typhoid toxin, which is in contrast to other known AB 5 Toxin-treated   1  21  41  61  81  101  121  141  161  181  201  221  241  261  281  301  321  341  361  381  401  421  441  461  481  501  521  541  561  581  601 Average RFU (±s.d.)
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toxins that have only one A subunit 9, 21 . The pyramid-shaped complex has a height of ,90 Å and a maximum width of ,60 Å ( Fig. 3a) , with CdtB located at the vertex, connected by PltA to a pentameric disc at the base of the pyramid made of five monomers of PltB ( Fig. 3a, b ). The tandem linear arrangement of the enzymatic subunits PltA and CdtB dictates that there are no interactions between CdtB and PltB. As predicted by the amino acid sequence similarities, the PltA and CdtB subunits have a structure very similar to that of the pertussis toxin S1 (and other ADP ribosyl transferases) 22 and to the CdtB subunit of cytolethal distending toxin 23 . PltA aligns very well to the pertussis toxin S1 domain with a root-mean-squared deviation (r.m.s.d.) of 2.168 Å over 140 Ca atoms (with 31% sequence identity) ( Supplementary Fig. 8 ). The positions of the conserved catalytic residues (Glu 133 in typhoid toxin and Glu 129 in pertussis toxin S1), as well as the disulphide bonds (Cys 56-Cys 207 in typhoid toxin and Cys 41-Cys 201 in pertussis toxin S1) overlap almost completely ( Supplementary Fig. 8 ). The latter indicates that, similarly to the pertussis toxin S1 subunit 24 , PltA would have to be reduced to allow the access of NAD and its putative substrates to the active site, and consequently, a reducing activating step must be necessary before contacting its host cell target(s). Typhoid toxin CdtB aligns very well to the Haemophilus ducreyi CdtB with an r.m.s.d. of 0.947 Å over 206 Ca atoms (with 52% sequence identity) ( Supplementary Fig. 9 ). The positions of the conserved catalytic residues in Typhoid toxin's CdtB overlap almost completely with those of its homologue in H. ducreyi. Similar to the B subunits of other AB 5 toxins 9 , the PltB oligomer is arranged as a pentamer with a central channel that is lined by five helices (Fig. 3b ). The PltB protomer shows a typical oligosaccharidebinding fold on the side of the pentamer ( Fig. 3c and Supplementary  Fig. 10 ), a location similar to that of toxins that preferentially bind glycoproteins, but different from those that preferentially bind glycolipids, which have the sugar-binding pockets on the membrane-proximal face of the toxin 9 . These findings are consistent with the observation that typhoid toxin preferentially binds glycans present on surface glycoproteins over those present on glycolipids ( Supplementary Tables 1  and 2 ). The monomer of typhoid holotoxin PltB aligns very well with SubB, the subtilase cytotoxin B subunit, with an r.m.s.d. of ,0.5 Å over 97 Ca atoms (with 50% sequence identity) ( Supplementary Fig. 10 ). Of note, the position of the conserved putative sugar-binding residue Ser 35 overlaps very well ( Fig. 3c and Supplementary Fig. 10 ). The predicted sugar-binding pocket in PltB is not as deep and seems more extended than in SubB, which also differs in surface-charge distribution (Fig. 3c ). These differences may account for the significantly different binding specificities shown by these two toxins 25 . We also compared PltB to the pertussis toxin S2 B subunit 26 . Although their overall amino sequence similarity is low, the structures can be aligned very well around their sugar-binding domains with an r.m.s.d. of 1.752 Å over 80 Ca atoms ( Supplementary Fig. 10 ). Residues in pertussis toxin S2 involved in sugar binding (Tyr 102, Ser 104, Arg 125) are well conserved in PltB (Tyr 33, Ser 35, Lys 59) (Fig. 3d) , and the charge distribution and architecture of the sugar-binding pockets are similar (Fig. 3c ). This is consistent with the observation that, despite overall less conservation, these two B subunits share sugar-binding specificity. For example, several of the glycans that bind typhoid toxin possess an Neu5Ac moiety at their terminal end, a determinant that also binds pertussis toxin 27 . Structural modelling of Neu5Ac bound to PltB predicts almost identical interaction to those observed in the atomic structure of pertussis toxin bound to Neu5Ac (Fig. 3c, d and Supplementary Fig. 11 ). Consistent with the structural predictions, a mutation in the sugar-binding pocket of PltB (PltB S35A ) abrogated the ability of typhoid toxin to bind glycans in glycoarray ( Fig. 4a and Supplementary Table 4 ) and surface plasmon resonance assays ( Supplementary Fig. 12 ), and the ability of the toxin to bind (Fig. 4b ) and intoxicate ( Fig. 4c ) cultured cells or to cause symptoms when systemically applied to mice (Fig. 4d) . These results are also consistent with the notion that there is a single carbohydrate-binding domain in typhoid toxin because the mutant abrogated binding to all carbohydrates. Surface plasmon resonance assays also indicated that on average, at least for the glycan tested (GD2), each PltB pentamer binds 2.5 sugar molecules with an affinity of , 1.2 mM (Supplementary Fig. 12 ). However, the glycoarray analysis predicts that the binding affinity is likely to be higher for more complex glycans.
The interaction of PltA with the PltB oligomer occurs largely through its carboxy terminus, which buries 1,657 Å 2 and has a DiG of 217.7 kcal mol 21 . A critical element in this interaction is a short helix at the carboxy-terminal end of PltA, which inserts into the hydrophobic lumen of the PltB channel ( Fig. 3b and Supplementary Fig. 13 ) and stabilizes the complex by critical interactions mediated by Pro 234, Val 235, Ile 236, Leu 238, Ile 239 and Leu 240 in PltA.
The most salient feature of the interface between PltA and CdtB is a disulphide bond between Cys 214 of PltA and Cys 269 of CdtB (Fig. 3e) . The rest of the interface between the two A subunits is unremarkable, burying only 950 Å 2 with a DiG of only 25.2 kcal mol 21 , indicating that the disulphide bound is essential for the integrity of the holotoxin. Consistent with this hypothesis, subjecting the typhoid toxin to reducing conditions resulted in the dissociation of CdtB from 
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the PltA-PltB complex (Fig. 4e ). Furthermore, introduction of a mutation in Cys 269 of CdtB destabilized the holotoxin complex in vitro (Fig. 4f) , and resulted in a loss of CdtB-dependent toxicity in S. Typhiinfected cells ( Fig. 4g and Supplementary Fig. 14) . This mutation also prevented the assembly of CdtB into its vesicle carrier intermediates that can be visualized as fluorescent puncta in S. Typhi-infected cells (Fig. 4h, i) , despite the fact that the mutant was expressed at equivalent levels to those of wild type ( Supplementary Fig. 15 ). These results indicate that the CdtB C269 -PltA C214 disulphide bond is critical for the assembly of typhoid toxin holotoxin in the periplasm of the bacteria. Remarkably, even though the sequence conservation between typhoid toxin's CdtB and that of its cytolethal distending toxin homologues is very high, the Cys 269 is unique to Typhoid toxin's CdtB (Fig. 4j) . Likewise, although all close homologues of PltA including ArtA, a closely related mono ADP ribosyl transferase from Salmonella enterica serovar Typhimurium 28 , have only two Cys that form an intramolecular disulphide bond, PltA is unique in that it has a third Cys (Cys 214) to pair with S. Typhi's CdtB (Fig. 4j) . Therefore typhoid toxin's CdtB has been specifically adapted for its tethering to the PltA-PltB complex by the evolution of uniquely positioned Cys residues in both PltA and CdtB. The covalent linkage of CdtB to the PltA-PltB complex by a disulphide bond ensures that CdtB and PltA are delivered simultaneously to the same target cell. Furthermore, this arrangement would ensure that, after endocytosis and retrograde transport to its place of translocation (most likely the endoplasmic reticulum), PltA and CdtB would be freed from one another upon reduction of the disulphide bond by local reductases, thus allowing them to become competent for translocation to the cytosol and delivery to their place of action.
This study provides unique insight into typhoid toxin, a critical virulence factor of S. Typhi, revealing unprecedented features for a bacterial exotoxin and providing significant information on the pathogenesis of typhoid fever. Although human experimentation will be required to confirm the relevance of these findings, the potential implication of typhoid toxin in the development of symptoms during the acute, life-threatening phase of typhoid fever may facilitate the development of potentially life-saving therapeutics against this disease.
METHODS SUMMARY
Wild-type S. Typhi strains have been described previously 29 . Mutants were constructed as described previously 30 . Protein purification and analysis, crystallization and structure determination were carried out following standard methods. Bacterial infections, mammalian cell intoxication and immunofluorescence microscopy were carried out as described previously 7 . Typhoid toxin binding assays were carried out with Oregon Green-488 (Invitrogen)-labelled toxin preparations by flow cytometry. Glycan array analysis was carried out at the Consortium for Functional Glycomics Protein-Glycan Interaction Core, at Emory University (http://www. functionalglycomics.org). labelled typhoid toxin containing PltB S35A was tested for its binding to glycans (a) and to cultured cells (b) (see Fig. 2 for details) (***P , 0.001 from at least three independent determinations). c, d, Alternatively, toxicity was assayed by flow cytometric cell-cycle analysis of toxin-treated cells (at least three independent experiments) (c), or by systemic administration to mice (n 5 3 to 5 mice) (d). e, The typhoid toxin complex was analysed by ion exchange chromatography before (blue) and after (red) treatment with DTT (L, loading control; M, molecular weight markers; F, chromatographic fraction). Inset shows SDS-PAGE analyses of the indicated fractions. f, A toxin preparation obtained from a bacterial strain expressing CdtB DCys 269 was analysed by gelfiltration chromatography and compared to wild-type toxin (the experiment was repeated two times). Whereas wild-type holotoxin eluted in fractions 13 and 14, toxin obtained from a bacterial strain encoding CdtB DCys 269 eluted in fractions 14 and 15 due to the lack of CdtB. g, Henle-407 cells were infected with S. Typhi strains encoding Flag-tagged CdtB or CdtB DCys 269 and cells were examined for toxicity by flow cytometry. h, i, Alternatively, cells were fixed, stained with anti-Flag antibody, and the amount of puncta staining, which represent CdtB in typhoid toxin export carriers 8 , were determined by immunofluorescence analysis. Bar represents average of puncta-associated fluorescence intensity (at least 100 cells were analysed in three independent experiments). ***P , 0.0001, Scale bar, 10 mm. 
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METHODS
Bacterial strains, mammalian cells and growth conditions. The wild-type Salmonella enterica serovar Typhi strain ISP2825 has been described previously 29 . A derivative of this strain encoding a Flag-epitope tagged CdtB has been previously described 7 . Other S. Typhi mutant strains were constructed by allelic exchange following previously described procedures 30 . Site-directed mutations and epitope tagging was carried out following standard recombinant DNA procedures. For all infection experiments, S. Typhi strains were grown at 37 uC in 2 ml LB broth containing 0.3 M NaCl to an OD 600 nm of ,0.9 after inoculation from overnight cultures at a dilution of 1:50. Cultured cells and culture medium used in these studies were as follows Typhoid toxin expression and purification. pltB, pltA and cdtB (wild-type or mutant alleles, and 3 3 Flag-or 6 3 His-tagged at the carboxy terminus of CdtB or internally in the case of PltA, as indicated) were cloned as a single operon in either a low copy plasmid derived from pWSK129 31 , or in pET28a1 (Novagen). Escherichia coli strains carrying the different plasmids were grown to an D 600 nm of 0.6-0.7 at 37 uC; expression of typhoid toxin was subsequently induced by the addition of 0.5 mM IPTG, and induced cultures were incubated overnight at 30 uC. Bacterial cells were pelleted by centrifugation, and bacterial cells were resuspended in a buffer containing 200 mM Tris-HCl (pH 7.5), 20% sucrose, 1 mM EDTA, 2 mg ml 21 lysozyme, and 13 protease inhibitors (2 ml per each gram of wet cell pellet weight), incubated for 5 min at room temperature, mixed with dH 2 O (3 ml per each gram of wet cell pellet weight) by inversion, and incubated for an additional 10 min on ice. A crude periplasmic protein fraction was obtained by centrifugation at 4,000g for 15 min at room temperature, and used as a source of typhoid toxin for affinity chromatography purification using M2 Flag affinity gel (Sigma). The periplasmic fraction containing typhoid holotoxin was incubated for 3 h at 4 uC with M2 agarose beads packed on a 10 ml column (Bio-Rad), washed with ,20 bed volume of PBS, and eluted twice with PBS containing 33Flag peptide (Sigma; 150 ng ml 21 ). Partially purified holotoxin was applied on a Superdex 200 size-exclusion chromatography (Tris-HCl buffer, 15-50 mM, in a pH range of 7.6-8.0 supplemented with 150 mM NaCl) to complete its purification. His-epitope-tagged typhoid toxin was purified as follows. E. coli cultures were resuspended in a buffer containing 15 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mg ml 21 lysozyme, 10 mg ml 21 DNase and 13 protease inhibitor cocktail, lysed by passing them through a French press three times, pelleted, and affinity-purified using a Nickel-resin (Qiagen) according to the vendor's recommendation. The eluates were diluted in 20 mM MES, pH 6.0 buffer and loaded onto a Hi Trap ion-exchange column. Fractions from the ion-exchange chromatography were monitored on SDS-PAGE, concentrated, and further purified by using a Superdex 200 column. Final fractions were examined for purity on a 15% SDS-PAGE. Mammalian cell intoxication assay. Cell-cycle arrest after typhoid toxin intoxication was examined by flow cytometry as previously described 7 . Briefly, after treatment with 33Flag-tagged typhoid toxin or bacterial infection for different times (as indicated), cells were trypsinized, collected, washed and fixed overnight at 220 uC in ,70% ethanol/PBS. Fixed cells were washed with PBS and resuspended in 500 ml of PBS containing 50 mg ml 21 propidium iodide, 0.1 mg ml 21 RNase A and 0.05% Triton X-100. After incubation for 40 min at 37 uC, cells were washed with PBS, resuspended in 500 ml PBS, filtered and analysed by a flow cytometry. DNA contents of cells was determined using FlowJo (Treestar randomly allocated in each group and numbers of animals per each group were estimated to obtain statistically significant data after a pilot experiment to get a sense of the potential variability. Groups of mice were intravenously injected with 100 ml solutions containing either TBS buffer alone or 10 mg of each of the purified holotoxin preparations (endotoxin free). His-tagged wild-type, PltA catalytic mutant (PltA E133A ), CdtB catalytic mutant (CdtB H160Q ), double catalytic mutant (PltA E133A CdtB H160Q ), and PltB S35A mutant holotoxins were purified as indicated above. Changes in behaviour, weight and temperature of the toxin-injected mice as well as their survival were closely monitored during the duration of the experiment. To minimize bias, blind end-point assessment was applied to examine the behaviour of the animals after toxin inoculation. Peripheral blood leukocyte preparation, immunostaining and flow cytometry analysis. Peripheral blood samples of typhoid toxin treated and control mice were collected into heparinized tubes, incubated with 1 ml ACK lysis buffer (BioWhittaker) (to remove red blood cells), incubated for 5 min on ice, washed with 2 ml PBS, and centrifuged to collect peripheral blood leukocytes (PBLs). After a repetition of the red blood cell removal step, PBLs were used for immunostaining as described below. After washing, the cells were immediately incubated for 30 min on ice with 100 ml of anti-mouse Ly-6G (Gr-1) antibody conjugated with FITC (eBioscience, cat. no. 11-5931-81). The cells were then washed with 2 ml FACS buffer (PBS, 0.16% BSA), resuspended in 100 ml FACS fixation buffer (PBS, 1% paraformaldehyde, 1% FCS), and used for flow cytometric analyses on a FACSCalibur flow cytometer (BD Biosciences). Alternatively, blood samples collected by heart puncture 4 days after toxin treatment were analysed in a Hemavet 950FS haematology analyser (Drew Scientific). Identification of typhoid toxin interacting, biotin-labelled host cell surface proteins. Cultured cells (Henle, Jurkat, Ramos or THP1 at ,50% confluency) were washed with PBS, treated with PBS containing ,100 mg ml 21 of Sulfo-NHS-SS-Biotin (Thermo) for 30 min at room temperature, and subsequently washed 3 times with 50 mM Tris-HCl pH 8.0/150 mM NaCl buffer to quench and to remove extra biotin reagent. After additional washings (3 times with PBS), cells were resuspended in a lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, and 13 protease inhibitor, incubated for 20 min on ice, and homogenized by passing a 26-G needle ,20 times. After removal of cellular debris by centrifugation, the supernatants were mixed with 10 mg purified Flag-tagged typhoid toxin and incubated for 3 h at 4 uC. Anti-Flag antibody-containing agarose beads were added, incubated for additional 1 h at 4 uC, washed 5 times with PBS, SDS-PAGE sample buffer was added, boiled, and run on SDS-PAGE. The gels were transferred to nitrocellulose membranes, blocked with TBS containing 5% BSA, incubated overnight at 4 uC with streptavidin conjugated to horseradish peroxidase (1:5,000) in TBS with 1% BSA, washed with TBST, and developed with ECL substrates (Pierce). To identify the typhoid toxin-interacting proteins by LC-MS/MS, equivalently obtained samples were run in parallel, stained with Coomassie blue, and gel regions corresponding to the molecular weight of typhoid-toxin interacting proteins identified by western blot analysis were excised and processed for LC-MS/MS as previously described 32 . Briefly, gel slices were destained in destaining buffer (50 mM NH 4 HCO 3 50% acetonitrile (ACN)), and dehydrated with ACN. Disulphide bonds were reduced by incubating the samples with NH 4 HCO 3 containing 10 mM DTT and alkylated by incubating them with 55 mM 2-iodoacetamide in 100 mM NH 4 HCO 3 buffer for 20 min at room temperature. Gel pieces were dehydrated, trypsin-digested overnight, extracted, run on an LTQ-Velos Mass Spectrometer, and spectra analysed with Mascot (Matrixscience). As negative controls, equivalently processed samples obtained with two irrelevant baits (glutathione S-transferase-conjugated with 33Flag and InvC-33Flag) were used. Oregon Green 488 typhoid toxin labelling. Purified wild type and PltB S35A mutant typhoid toxin preparations were fluorescently labelled with Oregon Green (OG)-488 dye (Invitrogen) according to the vendor's recommendation. OG-488 dye has a succinimidyl ester moiety that reacts with primary amines of proteins to form stable dye-protein conjugates. Purified toxin preparations (1 mg ml 21 ) were incubated with reactive dye in 500 ml of 100 mM bicarbonate buffer for 1 h at room temperature, and applied to a size-exclusion chromatography column provided by the vendor to separate the dye-protein conjugates from free dye. Degree of labelling was determined by measuring the absorbance of the conjugate solution at 280 nm and 496 nm, which yielded comparable toxin labelling for both toxin preparations (4.4:1 and 4.36:1 dye/holotoxin ratios for wild-type and PltB S35A mutant toxin, respectively). A predicted extinction coefficient of 191,400 M 21 cm 21 was used to calculate the dye/toxin ratio. Typhoid toxin binding assay. Cells were collected by trypsinization, washed with HBSS, resuspended in 100 ml HBSS containing 0.2 mg of Oregon Green-488 (Invitrogen)-labelled purified wild type or mutant toxin preparations. Cells were incubated in the presence of the labelled toxin preparations for 30 min at room temperature, washed with PBS, resuspended in 100 ml PBS containing 1% paraformaldehyde, and LETTER RESEARCH
